GENE BY GENE LTD
NPI 1881034064
Clinical Medical Laboratory in Houston, TX

Areas of Expertise

The following services and procedures, recently provided to Medicare patients, illustrate the range of care this provider offers. This list reflects the variety of services available to all patients visiting the practice and is based on 2022 Medicare dataset. In general, the more frequently a provider treats specific conditions or performs particular procedures, the more experienced they become in addressing similar patient needs. The provider has delivered many of the services listed below to Medicare patients. Please note that this list does not include services provided to patients who are not covered by Medicare.

2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r

This service involves the testing for COVID-19 using advanced technologies that can process multiple samples at once. It identifies different types or subtypes of the virus, including SARS-CoV-2/2019-nCoV. This test is non-CDC but adheres to the guidelines outlined in CMS-2020-01-R.

This service was performed 3,360 times for 658 patients

Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen

This is a lab test that detects the presence of COVID-19 in your body. It uses a technique to amplify the virus's genetic material, either DNA or RNA, making it easier to identify. A positive result indicates an active infection.

This service was performed 127 times for 43 patients

Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b

This test detects the presence of SARS-CoV-2 (COVID-19) and Influenza types A and B in your body. It uses a method called the multiplex amplified probe technique to amplify and identify specific virus genes. It helps in early diagnosis and appropriate treatment.

This service was performed 11,115 times for 1,031 patients

Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within

This is a test to detect the COVID-19 virus. It uses a technique that amplifies the virus's genetic material (DNA or RNA) for detection. High throughput technologies are used for rapid and large-scale testing. The procedure is completed within a set time frame.

This service was performed 2,523 times for 573 patients

Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source

Specimen collection for SARS-CoV-2, the virus causing COVID-19, involves taking a sample from the nose or throat using a swab. This sample is then analyzed in a lab to detect the presence of the virus. It's a crucial step in diagnosing COVID-19.

This service was performed 9,358 times for 870 patients

Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge

This service involves a healthcare professional traveling to collect necessary lab samples from patients who are homebound or in a nursing home. The travel allowance is a partial charge for the trip made to facilitate this service. It ensures medical care accessibility for all, regardless of mobility.

This service was performed 8,370 times for 750 patients

CLIA Information

The Clinical Laboratory Improvement Amendments (CLIA) of 1988 applies to facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. The CLIA Program sets standards for clinical laboratory testing and issues certificates. The NPI / CLIA crosswalk information for this NPI number is:

CLIA Number

45D1102202

Facility Type

Other - MOLECULAR GENETICS LABS

Certificate Effective Date

March 28, 2026

Certificate Expiration Date

March 27, 2028

Laboratory Director

DR. FENG ZHOU

Certificate Type

Certificate of Accreditation

Certificate Type Description

This is a CLIA certificate is issued to Gene By Gene Ltd on the basis of the laboratory's accreditation by an accreditation organization approved by CMS. This type of certificate is issued to a laboratories tha perform nonwaived (moderate and/or high complexity) testing.

Reviews for GENE BY GENE LTD

There are currently no reviews for this provider. Be the first person to share your experience with this provider by filling out our review form. Your insights are appreciated and will help others make informed decisions.

Frequently Asked Questions